Tag: CRO deviation trends

Thresholds for Escalating Deviations to Sponsors or Regulators

Posted on digi By digi

Thresholds for Escalating Deviations to Sponsors or Regulators When Should CROs Escalate Deviations to Sponsors or Regulators? Introduction: Why Escalation Thresholds Are Critical In clinical research, deviations are inevitable, but how Contract Research Organizations (CROs) handle them directly impacts patient safety, data credibility, and regulatory compliance. Regulators such as the FDA, EMA, and MHRA require…

Read More “Thresholds for Escalating Deviations to Sponsors or Regulators” »

CRO Audits, CAPA, and Deviation Management, Deviation Handling in CROs

Regulatory Perspectives on CRO Deviation Handling (FDA, EMA, MHRA)

Posted on digi By digi

Regulatory Perspectives on CRO Deviation Handling (FDA, EMA, MHRA) Understanding FDA, EMA, and MHRA Perspectives on CRO Deviation Handling Introduction: Why Regulatory Oversight Matters for Deviation Handling Contract Research Organizations (CROs) play a critical role in ensuring clinical trial compliance. As trial activities become increasingly outsourced, regulators such as the U.S. Food and Drug Administration…

Read More “Regulatory Perspectives on CRO Deviation Handling (FDA, EMA, MHRA)” »

CRO Audits, CAPA, and Deviation Management, Deviation Handling in CROs